Data validates Decipher Prostate Cancer Classifier in diagnosing the disease- GenomeDx Biosciences

GenomeDx Biosciences announced the first validation data supporting use of the Decipher Prostate Cancer Classifier in analysis of diagnostic needle core biopsies to help guide the management of newly diagnosed men with prostate cancer. Decipher, which has been extensively validated in over 3,000 patients for metastasis prediction after radical prostatectomy, accurately predicted 10-year post-operative metastasis from genomic analysis of diagnostic biopsy specimens.

Decipher scores were evaluated from a cohort of primarily low- and intermediate-risk disease patients with available needle biopsy tissue who went on to receive radical prostatectomy at Cleveland Clinic. Notably, Decipher reclassified 66.6% of intermediate-risk patients, as assessed by the National Comprehensive Cancer Network's (NCCN) guidelines' risk groups, into either lower (48.1%) or higher (18.5%) Decipher risk groups. The results of the study show the potential of Decipher to improve clinical decision-making even upon initial diagnosis of prostate cancer. The data will be presented at the 2016 Genitourinary Cancers Symposium in San Francisco.